What’s Fueling the Bull Run in Biotech Stocks?

Your next video will start in

Recommended Videos

  • Info

  • Comments


July 19 (Bloomberg) -- Bloomberg's Olivia Sterns examines the bull run in the biotech sector as the FDA approvals reach a 15-year high. She speaks on Bloomberg Television's "In The Loop."

It is about the pipelines.

We have seen huge innovation insights in the past couple of years, particularly in new drugs for cancer and rare diseases.

Biotech compared to the s&p 1500, the biotech sector has returned over 160% in the past three years, more than twice the s&p, the top performer's shares have surged tenfold.

One of the reasons for this huge outperformance, a more proactive fda moving more quickly to get more drugs approved.

They approved 39 novel drugs last year.

The fda is helping move things along, but why are the drugs more promising?

We have this revolution nymex.

Analyst ---- reovlution -- revolution in genomics.

We are starting to see the benefit and pay off.

One company has a drug that treats cystic fibrosis.

There shares have doubled since the start of this year alone.

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change